{"type":"trials","record":{"id":42235,"source_id":"clinicaltrials-gov","external_id":"NCT02140151","title":"Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration","brief_summary":"This study will determine whether quarterly injections of Ranibizumab may prevent eyes with dry age-related macular degeneration from progressing to wet age-related macular degeneration (AMD).","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Southern California Desert Retina Consultants, MC","enrollment":108,"countries":["United States"],"start_date":"2014-09-17","completion_date":"2020-07-09","last_update_date":"2022-08-25","source_url":"https://clinicaltrials.gov/study/NCT02140151","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"PREVENT","age_range":"50 Years","comparator":"Sham; Quarterly Ranibizumab 0.5mg","organization":"Southern California Desert Retina Consultants, MC","interventions":["Ranibizumab 0.5mg"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Development of exudative AMD — 2 years","Vision change — 2 years","Vision loss — 2 years","Number of injections — 2 years","Baseline predictive factors — 2 years","Development of geographic atrophy (GA) — 2 years","Ocular adverse events — 2 years","Systemic adverse events — 2 years"],"design_description":"RANDOMIZED · PARALLEL · PREVENTION · SINGLE","source_has_results":false},"controlled_terms":["Age-related Macular Degeneration","Ranibizumab 0.5mg"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02140151","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-09-17 to 2020-07-09","comparator":"Sham; Quarterly Ranibizumab 0.5mg","confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.939Z","intervention":["Ranibizumab 0.5mg"],"participants":108,"study_design":"RANDOMIZED · PARALLEL · PREVENTION · SINGLE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Development of exudative AMD — 2 years","Vision change — 2 years","Vision loss — 2 years","Number of injections — 2 years","Baseline predictive factors — 2 years","Development of geographic atrophy (GA) — 2 years","Ocular adverse events — 2 years","Systemic adverse events — 2 years"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","abstract","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42235","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}